OBJECTIVES: To evaluate the evidence concerning gFOBT kits and to develop gFOBT standards to be implemented by the Ontario Colorectal Cancer (CRC) Screening Program (the "Program"). DESIGN AND METHODS: We evaluated 3 aspects of gFOBT kits: 1) performance factors; 2) usability factors; and 3) laboratory factors. We obtained information from the published literature, other countries that use gFOBT, the internet, and gFOBT kit manufacturers' instructions. RESULTS: The Program should use a single brand of gFOBT kit with sensitivity > or =40% and specificity > or =95% for the detection of CRC in repeated testing. The Program should regularly monitor gFOBT performance. Participants should not restrict their diets except for eliminating vitamin C supplements and citrus fruits and juices for 3 days prior to and during stool collection; participants should not discontinue taking aspirin (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs). The Program should use one or a limited number of labs; leak-proof envelopes should be used that protect samples during mailing; the lab should delay processing fecal samples for at least 48 h following stool collection; the lab should implement staff training and quality control protocols. CONCLUSIONS: The Program should monitor and report on its performance according to these standards, and should continually assess new evidence related to CRC screening methods.
OBJECTIVES: To evaluate the evidence concerning gFOBT kits and to develop gFOBT standards to be implemented by the Ontario Colorectal Cancer (CRC) Screening Program (the "Program"). DESIGN AND METHODS: We evaluated 3 aspects of gFOBT kits: 1) performance factors; 2) usability factors; and 3) laboratory factors. We obtained information from the published literature, other countries that use gFOBT, the internet, and gFOBT kit manufacturers' instructions. RESULTS: The Program should use a single brand of gFOBT kit with sensitivity > or =40% and specificity > or =95% for the detection of CRC in repeated testing. The Program should regularly monitor gFOBT performance. Participants should not restrict their diets except for eliminating vitamin C supplements and citrus fruits and juices for 3 days prior to and during stool collection; participants should not discontinue taking aspirin (ASA) or non-steroidal anti-inflammatory drugs (NSAIDs). The Program should use one or a limited number of labs; leak-proof envelopes should be used that protect samples during mailing; the lab should delay processing fecal samples for at least 48 h following stool collection; the lab should implement staff training and quality control protocols. CONCLUSIONS: The Program should monitor and report on its performance according to these standards, and should continually assess new evidence related to CRC screening methods.
Authors: Linda Rabeneck; R Bryan Rumble; Frank Thompson; Michael Mills; Curtis Oleschuk; Alexandra Whibley; Hans Messersmith; Nancy Lewis Journal: Can J Gastroenterol Date: 2012-03 Impact factor: 3.522
Authors: L von Karsa; J Patnick; N Segnan; W Atkin; S Halloran; I Lansdorp-Vogelaar; N Malila; S Minozzi; S Moss; P Quirke; R J Steele; M Vieth; L Aabakken; L Altenhofen; R Ancelle-Park; N Antoljak; A Anttila; P Armaroli; S Arrossi; J Austoker; R Banzi; C Bellisario; J Blom; H Brenner; M Bretthauer; M Camargo Cancela; G Costamagna; J Cuzick; M Dai; J Daniel; E Dekker; N Delicata; S Ducarroz; H Erfkamp; J A Espinàs; J Faivre; L Faulds Wood; A Flugelman; S Frkovic-Grazio; B Geller; L Giordano; G Grazzini; J Green; C Hamashima; C Herrmann; P Hewitson; G Hoff; I Holten; R Jover; M F Kaminski; E J Kuipers; J Kurtinaitis; R Lambert; G Launoy; W Lee; R Leicester; M Leja; D Lieberman; T Lignini; E Lucas; E Lynge; S Mádai; J Marinho; J Maučec Zakotnik; G Minoli; C Monk; A Morais; R Muwonge; M Nadel; L Neamtiu; M Peris Tuser; M Pignone; C Pox; M Primic-Zakelj; J Psaila; L Rabeneck; D Ransohoff; M Rasmussen; J Regula; J Ren; G Rennert; J Rey; R H Riddell; M Risio; V Rodrigues; H Saito; C Sauvaget; A Scharpantgen; W Schmiegel; C Senore; M Siddiqi; D Sighoko; R Smith; S Smith; S Suchanek; E Suonio; W Tong; S Törnberg; E Van Cutsem; L Vignatelli; P Villain; L Voti; H Watanabe; J Watson; S Winawer; G Young; V Zaksas; M Zappa; R Valori Journal: Endoscopy Date: 2012-12-04 Impact factor: 10.093
Authors: M Elisabeth Del Giudice; Emily T Vella; Amanda Hey; Marko Simunovic; William Harris; Cheryl Levitt Journal: Can Fam Physician Date: 2014-08 Impact factor: 3.275
Authors: M Elisabeth Del Giudice; Emily T Vella; Amanda Hey; Marko Simunovic; William Harris; Cheryl Levitt Journal: Can Fam Physician Date: 2014-08 Impact factor: 3.275
Authors: Desmond J Leddin; Robert Enns; Robert Hilsden; Victor Plourde; Linda Rabeneck; Daniel C Sadowski; Harminder Signh Journal: Can J Gastroenterol Date: 2010-12 Impact factor: 3.522